Watson Robert Eugene
Known title: DirectorCIK: 0001511858
Watson Robert Eugene's purchase track record
Watson Robert Eugene has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/25/2025 | CVM | $20K | +11.7% | -28.9% | +8.3% |
| 5/8/2024 | CVM | $28K | -15.8% | -45.3% | +14.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CVM | ▲ Buy | Open Market | 2,919 | $20K | 7/25/2025 | View on chart |
| CVM | ▲ Buy | Open Market | 20,000 | $28K | 5/8/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Cel-Sci stock shows high RSI and revenue divergence
Recent data for Cel-Sci Corporation indicates a high RSI reading of 85.6, suggesting the stock may be overbought. The company is also showing a six-month revenue and price divergence. Analysts maintain an average target price of $12.50, which is significantly higher than the current trading levels within the 52-week range.
Cel-Sci stock shows high RSI and revenue divergence. Recent data for Cel-Sci Corporation indicates a high RSI reading of 85.6, suggesting the stock may be overbought. The company is also showing a six-month revenue and price divergence. Analysts maintain an average target price of $12.50, which is significantly higher than the current trading levels within the 52-week range.